Q-omics provides the consensus-scored SNHG11 profile across patient tissues and cancer cell-line models. SNHG11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNHG11 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SNHG11 RNA expression shows 18,438 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where SNHG11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG11 survival associations across molecular data types. SNHG11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG11 RNA expression–survival associations across cancer types. High SNHG11 expression shows unfavorable associations in UVM, KIRC, LGG and LIHC, but favorable associations in BRCA and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNHG11 RNA expression.
This table summarizes SNHG11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG11 shows higher tumor expression in KIRC, COAD, BLCA, HNSC, LIHC and STAD. The KIRC box plot shows higher SNHG11 RNA expression in tumor versus normal tissue (log2 FC = +0.237, t-test p < 0.001).
This table shows molecular features associated with SNHG11 in patient tissues and cancer cell lines. In patient samples, SNHG11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
